成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  2. Apoptosis Anti-infection
  3. Ferroptosis Fungal
  4. Ferrostatin-1

Ferrostatin-1  (Synonyms: Fer-1)

目錄號: HY-100579 純度: 99.71%
COA 產(chǎn)品使用指南

Ferrostatin-1 (Fer-1) 是一種有效的、選擇性的 ferroptosis 抑制劑，抑制 Erastin 誘導(dǎo)的 HT-1080 細(xì)胞鐵死亡 (EC50=60 nM)。Ferrostatin-1 是一種人工合成的抗氧化劑，通過還原機(jī)制來防止膜脂的損傷，從而抑制細(xì)胞死亡。Ferrostatin-1 具有抗真菌活性。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報，我們不為任何個人用途提供產(chǎn)品和服務(wù)

Ferrostatin-1 Chemical Structure

Ferrostatin-1 Chemical Structure

CAS No. : 347174-05-4

1.  客戶無需承擔(dān)相應(yīng)的運(yùn)輸費(fèi)用。

2.  同一機(jī)構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機(jī)構(gòu)（單位）一年內(nèi)

     可免費(fèi)申領(lǐng)三個不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價格 是否有貨 數(shù)量
10 mM * 1 mL in DMSO ￥726
In-stock
5 mg ￥660
In-stock
10 mg ￥1150
In-stock
25 mg ￥2450
In-stock
50 mg ￥4200
In-stock
100 mg 現(xiàn)貨 詢價
200 mg   詢價  
500 mg   詢價  

* Please select Quantity before adding items.

Customer Review

Other Forms of Ferrostatin-1:

MCE活性驗證

以上結(jié)果經(jīng)由 MCE 實(shí)驗室檢測獲得。

MCE 顧客使用本產(chǎn)品發(fā)表的 741 篇科研文獻(xiàn)

WB
Cell Viability Assay
Proliferation Assay
IF

    Ferrostatin-1 purchased from MCE. Usage Cited in: J Funct Foods. 2023 May.

    Ferrostatin-1 (Fer-1) significantly restores the decreased cell viability in HK-1 and 5-8F cells induced by α-solanine.

    Ferrostatin-1 purchased from MCE. Usage Cited in: Sleep Breath. 2023 Mar 1.  [Abstract]

    The protein content of GPX4 and FTH1 is signifcantly upregulated in intermittent hypoxia (IH)+ferrostatin-1 (5 μM) group, in rat liver (BRL?3A) cells.

    Ferrostatin-1 purchased from MCE. Usage Cited in: Cell Discov. 2022 May 3;8(1):40.  [Abstract]

    U2OS cells are incubated with DMSO or OSMI-1 for 12?h and then pre-treated with Ferrostatin-1 (Fer-1; 2?μM) for 2?h before the treatment of RSL3 for 4?h. Cells are stained with PI and cell death is then assessed by flow cytometry.

    Ferrostatin-1 purchased from MCE. Usage Cited in: Redox Biol. 2022 Oct;56:102435.  [Abstract]

    Primary HSCs and LX-2 cells are treated with EA (LX-2 cells: 40 μM; primary HSCs: 45 μM), Ferrostatin-1 (1 μM) and ZVAD-FMK (10 μM), and cells are stained with PI (red fluorescence) to examine the dead cells.

    Ferrostatin-1 purchased from MCE. Usage Cited in: EBioMedicine. 2022 Feb;76:103847.  [Abstract]

    Mitochondrial membrane potential (ΔΨm) measured by fluorescence microscopy of MCC treated with TBHP and rescued via Ferrostatin-1 (Fer-1; 1 μM) using JC-1 Mitochondrial Membrane Potential Assay. In Fer-1 and DFO group, red fluorescence (poly JC-1) is increased and green fluorescence (mono JC-1) is decreased.

    Ferrostatin-1 purchased from MCE. Usage Cited in: Bioact Mater. 2021 Nov 19;13:23-36.  [Abstract]

    H1299 and H460 cells are treated with Curcumenol with or without Ferrostatin-1 (Fer-1; 1 μM) for 24 h, and the cell viability is analyzed.

    Ferrostatin-1 purchased from MCE. Usage Cited in: J Exp Clin Cancer Res. 2021 Jun 23;40(1):206.  [Abstract]

    T47D cells are treated with Metformin (5?mM) for 48?h in the absence or presence of Ferrostatin-1 (1?μM) for 48?h.

    Ferrostatin-1 purchased from MCE. Usage Cited in: Cancer Lett. 2021 Jul 10;510:93-104.  [Abstract]

    Ferrostatin-1(2 μM) has the ability to fully restore the cell viability impaired by Erastin (5 μM) treated control cells in GBC-SD cells.

    Ferrostatin-1 purchased from MCE. Usage Cited in: Int J Biol Sci. 2021 Mar 1;17(4):942-956.  [Abstract]

    After the gallic acid treatment, Fe2+, ROS, and MDA are significantly increased compared to the control group, and at the same time, the content of GSH is significantly reduced. The intervention of Ferrostatin-1 (2 μM) while treating the cells with gallic acid reversed the changes in these indicators to varying degrees.

    Ferrostatin-1 purchased from MCE. Usage Cited in: Int J Biol Sci. 2021 Mar 1;17(4):942-956.  [Abstract]

    Gallic acid affects the expression of ferroptosis-related proteins. The relative expression levels of GPX4, SLC7A11, and SIGMAR1 decreased, while the relative expression levels of ATF4 and TFR1 increased. Ferrostatin-1 (2 μM) as a ferroptosis inhibitor reverses the expression trend of these proteins.

    Ferrostatin-1 purchased from MCE. Usage Cited in: Signal Transduct Target Ther. 2020 May 8;5(1):51.  [Abstract]

    Erastin-induced cell death in lung cancer cells is almost blocked by cotreatment with the Ferrostatin-1 (Fer-1; 24?h) in H460 and H1299 cells.

    Ferrostatin-1 purchased from MCE. Usage Cited in: Theranostics. 2020 Aug 2;10(21):9865-9887.  [Abstract]

    p53 expression of HepG2 cells after treated with Fer-1 at a concentration of 0-40 nM. The addition of Fer-1 could repress the expression of p53 protein by inhibiting the ferroptosis of SFB formulation.

    Ferrostatin-1 purchased from MCE. Usage Cited in: Cell Death Dis. 2020 Sep 15;11(9):756.  [Abstract]

    Acot1 protein levels in different concentrations of DOX-treated HL-1 cell with or without Fer-1 (10?μM) for 24?h. Acot1 expression is decreased at a higher concentration of DOX, while Fer-1 co-treatment partially suppressed this trend.

    • 生物活性

    • 純度 & 產(chǎn)品資料

    • 參考文獻(xiàn)

    生物活性

    Ferrostatin-1 (Fer-1), a potent and selective ferroptosis inhibitor, suppresses Erastin-induced ferroptosis in HT-1080 cells (EC50=60 nM). Ferrostatin-1, a synthetic antioxidant, acts via a reductive mechanism to prevent damage to membrane lipids and thereby inhibits cell death. Ferrostatin-1 exhibits antifungal activity[1][2][3].

    IC50 & Target

    EC50: 60 nM (Ferroptosis)[1]
    細(xì)胞效力
    (Cellular Effect)
    Cell Line Type Value Description References
    Fibroblast EC50
    33 nM
    Compound: Fer-1
    Inhibition of erastin-induced cell death in FRDA patient-derived fibroblast assessed as depletion of cellular ATP incubated for 12 hrs followed by erastin stimulation and measured after by luciferase-linked ATPase enzymatic assay
    Inhibition of erastin-induced cell death in FRDA patient-derived fibroblast assessed as depletion of cellular ATP incubated for 12 hrs followed by erastin stimulation and measured after by luciferase-linked ATPase enzymatic assay
    		[PMID: 33214825]
    HT-1080 EC50
    0.07 μM
    Compound: Fer-1
    Anti-ferroptotic activity against Erastin-induced ferroptosis in human HT-1080 cells assessed as cell activity measured after 24 hrs by Cell Titer-Glo luminescent assay
    Anti-ferroptotic activity against Erastin-induced ferroptosis in human HT-1080 cells assessed as cell activity measured after 24 hrs by Cell Titer-Glo luminescent assay
    		[PMID: 35300093]
    HT-1080 EC50
    0.088 μM
    Compound: Fer-1
    Inhibition of erastin-induced ferroptosis in human HT-1080 cells assessed as cell viability incubated for 48 hrs by MTT assay
    Inhibition of erastin-induced ferroptosis in human HT-1080 cells assessed as cell viability incubated for 48 hrs by MTT assay
    		[PMID: 33065375]
    HT-1080 IC50
    95 nM
    Compound: 1; fer-1
    Antiferroptotic activity in human HT1080 cells assessed as inhibition of erastin-induced cell death by Alamar blue assay
    Antiferroptotic activity in human HT1080 cells assessed as inhibition of erastin-induced cell death by Alamar blue assay
    		[PMID: 26696014]
    HT-22 EC50
    81.2 nM
    Compound: Fer-1
    Anti-ferroptotic activity against RSL3-induced ferroptosis in human HT-22 cells assessed as cell viability measured after 24 hrs by MTT assay
    Anti-ferroptotic activity against RSL3-induced ferroptosis in human HT-22 cells assessed as cell viability measured after 24 hrs by MTT assay
    		[PMID: 35796002]
    IMR-32 IC50
    18 nM
    Compound: 1; fer-1
    Antiferroptotic activity in human IMR32 neuroblastoma cells assessed as inhibition of erastin-induced cell death preincubated for 1 hr before erastin stimulation and measured after 13 hrs by fluorescence plate reader method
    Antiferroptotic activity in human IMR32 neuroblastoma cells assessed as inhibition of erastin-induced cell death preincubated for 1 hr before erastin stimulation and measured after 13 hrs by fluorescence plate reader method
    		[PMID: 26696014]
    IMR-32 IC50
    33 nM
    Compound: 1; Fer-1
    Inhibition of erastin-induced ferroptosis in human IMR32 cells preincubated for 1 hr followed by erastin stimulation and measured after 13 hrs by sytox green-based fluorescence assay
    Inhibition of erastin-induced ferroptosis in human IMR32 cells preincubated for 1 hr followed by erastin stimulation and measured after 13 hrs by sytox green-based fluorescence assay
    		[PMID: 30354101]
    LLC-MK2 IC50
    > 240 μM
    Compound: AA1
    Cytotoxicity against monkey LLC-MK2 cells after 96 hrs by Alamar Blue assay
    Cytotoxicity against monkey LLC-MK2 cells after 96 hrs by Alamar Blue assay
    		[PMID: 26410073]
    Lymphocyte EC50
    48 nM
    Compound: Fer-1
    Anti-ferroptotic activity in FRDA patient-derived Lymphocyte assessed as reduction in RSL3-induced lipid peroxidation incubated for overnight followed by RSL3 stimulation and measured after 90 mins by FACS analysis
    Anti-ferroptotic activity in FRDA patient-derived Lymphocyte assessed as reduction in RSL3-induced lipid peroxidation incubated for overnight followed by RSL3 stimulation and measured after 90 mins by FACS analysis
    		[PMID: 33214825]
    NIH3T3 IC50
    0.22 μM
    Compound: Fer-1
    Inhibition of TBHP-induced ferroptosis in mouse NIH/3T3 cells after 12 hrs by WST-8 assay
    Inhibition of TBHP-induced ferroptosis in mouse NIH/3T3 cells after 12 hrs by WST-8 assay
    		[PMID: 31531196]
    NIH3T3 IC50
    0.27 μM
    Compound: Fer-1
    Inhibition of erastin-induced ferroptosis in mouse NIH/3T3 cells after 24 hrs by WST-8 assay
    Inhibition of erastin-induced ferroptosis in mouse NIH/3T3 cells after 24 hrs by WST-8 assay
    		[PMID: 31531196]
    RAW264.7 EC50
    0.04 μM
    Compound: Fer-1
    Anti-ferroptotic activity against RSL-3 induced ferroptosis in mouse RAW264.7 cells assessed as cell activity measured after 24 hrs by Cell Titer-Glo luminescent assay
    Anti-ferroptotic activity against RSL-3 induced ferroptosis in mouse RAW264.7 cells assessed as cell activity measured after 24 hrs by Cell Titer-Glo luminescent assay
    		[PMID: 35300093]
    體外研究
    (In Vitro)

    Ferrostatin-1 可防止 erastin 誘導(dǎo)的細(xì)胞溶質(zhì)和脂質(zhì) ROS 積累。 Ferrostatin-1 可預(yù)防器官型大鼠腦切片中谷氨酸誘導(dǎo)的神經(jīng)毒性[1]。
    Ferrostatin-1（2 μM；24 小時）可防止大鼠器官型海馬切片培養(yǎng)物 (OHSC) 中谷氨酸 (5 mM) 誘導(dǎo)的神經(jīng)毒性[2]。
    Ferrostatin-1 抑制脂質(zhì)過氧化，但不抑制線粒體活性氧的形成或溶酶體膜通透性[2]。
    Ferrostatin-1 在亨廷頓病 (HD)、腦室周圍白質(zhì)軟化癥 (PVL) 和腎功能障礙的細(xì)胞模型中抑制細(xì)胞死亡[2]。
    Ferrostatin-1（1 μM；6 小時）抑制 HT-1080 細(xì)胞中不飽和脂肪酸的氧化破壞，從而增加健康的中型多棘神經(jīng)元 (MSN) 的數(shù)量[3]。


    鐵死亡敏感細(xì)胞系

    敏感細(xì)胞系 Ferrostatin-1 實(shí)驗條件 鐵死亡誘導(dǎo)劑
    HT-1080[1] 0.5 μM; 24 h; EC50=60 nM Erastin (10 nM-100 μM; 24 h)
    BEAS-2B[4] 2 μM; 16 h LPS (10 mg/L; 16 h)
    PC12 (differentiated)[5] 1 μM; 12 h Erastin (7.5 μM; 12 h)
    N27 neuron[8] 0.004-0.25 μM; 24 h; EC50=0.039 μM RSL3 (1 μM; 24 h)
    BMSCs[9] 1 μM; 24 h GSDH (10-50 μM; 24 h)
    HT-22[10] 3-12 μM; 16 h Glutamate (5 mM; 16 h)
    HK?2[11] 100 μM; 24 h Oxalate (2 mM; 24 h)
    MLE12[12] 1 and 5 μM; 24 h 8% and 20% cyclic stretching (CS)
    HaCaT[13] 10 μM UVB (20mJ/cm2)
    小鼠原代星形膠質(zhì)細(xì)胞[14] 0.1-2 μM; 24 h Angiotensin II (10 μM; 24 h)
    SKOV3[15] 5 μM; 24 h Erastin (10 μM; 24 h)
    OVCA429[15] 10 μM; 24 h Erastin (20 μM; 24 h)
    HK-2 WT[16] 先 2 μM 預(yù)處理，后與誘導(dǎo)劑共處理 8 h RSL3 (0.01-1 μM; 8 h)
    MDA-MB-468[16] 先 2 μM 預(yù)處理 1 h，后與誘導(dǎo)劑共處理 2 h RSL3 (500 nM; 2 h)
    NCI-H1299[16] 先 2 μM 預(yù)處理，后與誘導(dǎo)劑共處理 18 h Erastin (5 μM; 18 h)
    HT22 neuron[17] 先用誘導(dǎo)劑預(yù)處理，后用 10 和 20 μM Ferrostatin-1 共處理 6, 12 或 24 h Erastin (0 和 5 μM; 12 h)
    HT22 neuron[18] 先 2 μM 預(yù)處理 30 min，后與誘導(dǎo)劑共處理 24 h Erastin (1 μM; 24 h)
    HT-1080[19] 0.5 μM; 12 h Erastin (10 μM; 12 h)
    H1975[20] 先 2 μM 預(yù)處理 14 h, 后用誘導(dǎo)劑共處理 24 h RSL3 (1 μM; 6 或 24 h)
    A549[20] 先 2 μM 預(yù)處理 14 h, 后用誘導(dǎo)劑共處理 24 h RSL3 (1 μM; 6 或 24 h)

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    體內(nèi)研究
    (In Vivo)

    Ferrostatin-1（5 mg/kg；腹腔注射；單劑量，處理于甘油注射前 30 分鐘）改善橫紋肌溶解小鼠的腎功能，而泛半胱天冬酶抑制劑 zVAD 或 RIPK3 缺陷小鼠未觀察到有益效果 [1].
    Ferrostatin-1（0.8 mg/kg；尾靜脈注射）有效緩解LPS誘導(dǎo)的急性肺損傷（ALI）[4]。
    Ferrostatin-1（5 mg/kg；腹腔注射；C57BL/6J 小鼠）改善橫紋肌溶解癥小鼠的腎功能[5]。
    Ferrostatin-1 (10 mg/kg/d, 腹腔注射, 3 d) 可在新生大鼠的大腦中減輕缺氧缺血性腦損傷-、氧葡萄糖剝奪-或 Erastin (HY-15763)-誘導(dǎo)的鐵死亡[6]。
    Ferrostatin-1 (0.655 mg/kg, 腹腔注射, 一周三次，共六周) 通過增加 GPX4 活性和抑制脂質(zhì)過氧化在卵巢切除 (絕經(jīng)后模型) 大鼠唾液腺中發(fā)揮抗鐵死亡作用[7]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Male C57BL/6 mice (LPS-induced ALI)[4]
    Dosage: 0.8?mg/kg
    Administration: Tail vein injection
    Result: Exerted therapeutic action against LPS-induced ALI.
    分子量

    262.35

    Formula

    C15H22N2O2
    CAS 號
    性狀

    固體

    顏色

    Gray to gray purple

    運(yùn)輸條件

    Room temperature in continental US; may vary elsewhere.
    儲存方式

    4°C, protect from light

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    溶解性數(shù)據(jù)
    細(xì)胞實(shí)驗： 

    DMSO 中的溶解度 : 125 mg/mL (476.46 mM; 超聲助溶; 吸濕的 DMSO 對產(chǎn)品的溶解度有顯著影響，請使用新開封的 DMSO)

    配制儲備液
    濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg
    1 mM 3.8117 mL 19.0585 mL 38.1170 mL
    5 mM 0.7623 mL 3.8117 mL 7.6234 mL
    查看完整儲備液配制表

    * 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
    儲備液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C儲存時，請在6個月內(nèi)使用，-20°C儲存時，請在1個月內(nèi)使用。

    • 摩爾計算器

    • 稀釋計算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質(zhì)量
    =
    濃度
    ×
    體積
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    濃度 (start)

    C1

    ×
    體積 (start)

    V1

    =
    濃度 (final)

    C2

    ×
    體積 (final)

    V2

    動物實(shí)驗：

    請根據(jù)您的 實(shí)驗動物和給藥方式 選擇適當(dāng)?shù)娜芙夥桨浮?

    以下溶解方案都請先按照 In Vitro 方式配制澄清的儲備液，再依次添加助溶劑：
    ——為保證實(shí)驗結(jié)果的可靠性，澄清的儲備液可以根據(jù)儲存條件，適當(dāng)保存；體內(nèi)實(shí)驗的工作液，建議您現(xiàn)用現(xiàn)配，當(dāng)天使用；
    以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶

    • 方案 一

      請依序添加每種溶劑： 10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.08 mg/mL (7.93 mM); 澄清溶液

      此方案可獲得 ≥ 2.08 mg/mL（飽和度未知）的澄清溶液。

      以 1 mL 工作液為例，取 100 μL 20.8 mg/mL 的澄清 DMSO 儲備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水 定容至 1 mL。

      生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。
    • 方案 二

      請依序添加每種溶劑： 10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.08 mg/mL (7.93 mM); 澄清溶液

      此方案可獲得 ≥ 2.08 mg/mL（飽和度未知）的澄清溶液。

      以 1 mL 工作液為例，取 100 μL 20.8 mg/mL 的澄清 DMSO 儲備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液 中，混合均勻。

      2 g SBE-β-CD（磺丁基醚 β-環(huán)糊精）粉末定容于 10 mL 的生理鹽水中，完全溶解至澄清透明。

    以下溶解方案，請直接配制工作液。建議現(xiàn)用現(xiàn)配，在短期內(nèi)盡快用完。 以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比； 如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶。

    • 方案 一

      請依序添加每種溶劑： 50% PEG300    50% Saline

      Solubility: 5 mg/mL (19.06 mM); 懸濁液; 超聲助溶

    動物溶解方案計算器
    請輸入動物實(shí)驗的基本信息：

    給藥劑量

    mg/kg

    動物的平均體重

    g

    每只動物的給藥體積

    μL

    動物數(shù)量

    只
    由于實(shí)驗過程有損耗，建議您多配一只動物的量
    請輸入您的動物體內(nèi)配方組成：
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    如果您的動物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。
    方案所需 助溶劑 包括：DMSO， ，均可在 MCE 網(wǎng)站選購。 ，Tween 80，均可在 MCE 網(wǎng)站選購。
    計算結(jié)果
    工作液所需濃度 : mg/mL
    儲備液配制方法 : mg 藥物溶于 μL  DMSO（母液濃度為 mg/mL）。

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    您所需的儲備液濃度超過該產(chǎn)品的實(shí)測溶解度，以下方案僅供參考，如有需要，請與 MCE 中國技術(shù)支持聯(lián)系。
    動物實(shí)驗體內(nèi)工作液的配制方法 : 取 μL DMSO 儲備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。
    連續(xù)給藥周期超過半月以上，請謹(jǐn)慎選擇該方案。
    請確保第一步儲備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱 （超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。
    純度 & 產(chǎn)品資料

    純度: 99.96%

    參考文獻(xiàn)

    完整儲備液配制表

    * 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
    儲備液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C儲存時，請在6個月內(nèi)使用，-20°C儲存時，請在1個月內(nèi)使用。

    可選溶劑 濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 3.8117 mL 19.0585 mL 38.1170 mL 95.2925 mL
    5 mM 0.7623 mL 3.8117 mL 7.6234 mL 19.0585 mL
    10 mM 0.3812 mL 1.9059 mL 3.8117 mL 9.5293 mL
    15 mM 0.2541 mL 1.2706 mL 2.5411 mL 6.3528 mL
    20 mM 0.1906 mL 0.9529 mL 1.9059 mL 4.7646 mL
    25 mM 0.1525 mL 0.7623 mL 1.5247 mL 3.8117 mL
    30 mM 0.1271 mL 0.6353 mL 1.2706 mL 3.1764 mL
    40 mM 0.0953 mL 0.4765 mL 0.9529 mL 2.3823 mL
    50 mM 0.0762 mL 0.3812 mL 0.7623 mL 1.9059 mL
    60 mM 0.0635 mL 0.3176 mL 0.6353 mL 1.5882 mL
    80 mM 0.0476 mL 0.2382 mL 0.4765 mL 1.1912 mL
    100 mM 0.0381 mL 0.1906 mL 0.3812 mL 0.9529 mL
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    您最近查看的產(chǎn)品:

    Your information is safe with us. * Required Fields.

       產(chǎn)品名稱：

    		  

    * 需求量：

    * 客戶姓名：

    		 

    * Email：

    * 電話：

    		 

    * 公司或機(jī)構(gòu)名稱：

       留言給我們：

    Bulk Inquiry

    Inquiry Information

    產(chǎn)品名稱：
    Ferrostatin-1
    目錄號：
    HY-100579
    需求量：